ChiCTR2000040684 版本V1.2 版本创建时间2021/03/22 04:52:46 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000040684 

最近更新日期:

Date of Last Refreshed on:

2021-03-22 04:51:53 

注册时间:

Date of Registration:

2020-12-08 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

嗜铬细胞瘤切除术中应用目标导向液体治疗对其预后的影响

Public title:

Effect of goal-directed fluid therapy on the prognosis of pheochromocytoma resection

注册题目简写:

English Acronym:

研究课题的正式科学名称:

嗜铬细胞瘤切除术中应用目标导向液体治疗对其预后的影响

Scientific title:

Effect of goal-directed fluid therapy on the prognosis of pheochromocytoma resection

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

龙波 

研究负责人:

赵雅丽 

Applicant:

Bo Long 

Study leader:

Yali Zhao 

申请注册联系人电话:

Applicant telephone:

+86 18940259927

研究负责人电话:

Study leader's telephone:

+86 17614044652

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

longb@sj-hospital.org

研究负责人电子邮件:

Study leader's E-mail:

1989046230@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国辽宁省沈阳市和平区三好街36号

研究负责人通讯地址:

中国辽宁省沈阳市和平区三好街36号

Applicant address:

36 Sanhao Street, Heping District, Shenyang, Liaoning, China

Study leader's address:

36 Sanhao Street, Heping District, Shenyang, Liaoning, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中国医科大学附属盛京医院

Applicant's institution:

Shengjing Hospital of China Medical University

研究负责人所在单位:

中国医科大学附属盛京医院

Affiliation of the Leader:

Shengjing Hospital of China Medical University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2020PS643K

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国医科大学附属盛京医院伦理委员会

Name of the ethic committee:

Ethics Committee of Shengjing Hospital affiliated to China Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2020-09-28 00:00:00

伦理委员会联系人:

赵玉虹

Contact Name of the ethic committee:

Zhao Yuhong

伦理委员会联系地址:

中国辽宁省沈阳市和平区三好街36号

Contact Address of the ethic committee:

36 Sanhao Street, Heping District, Shenyang, Liaoning, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中国医科大学附属盛京医院

Primary sponsor:

Shengjing Hospital of China Medical

研究实施负责(组长)单位地址:

中国医科大学附属盛京医院

Primary sponsor's address:

36 Sanhao Street, Heping District, Shenyang, Liaoning, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

辽宁

市(区县):

沈阳

Country:

China

Province:

Liaoning

City:

单位(医院):

中国医科大学附属盛京医院

具体地址:

中国辽宁省沈阳市和平区三好街36号

Institution
hospital:

Shengjing Hospital of China Medical University

Address:

36 Sanhao Street, Heping District, Shenyang

经费或物资来源:

自筹课题

Source(s) of funding:

Raise issues

Target disease:

pheochromocytoma

Target disease code:

研究类型:

预后研究

Study type:

Prognosis study

研究所处阶段:

I期临床试验 

Study phase:

1

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

本文旨在通过病例队列研究探讨嗜铬细胞瘤手术中应用FloTrac监测进行目标导向液体治疗对患者术后使用升压药物用量及住院时间的影响,并为临床应用提供理论依据。  

Objectives of Study:

The purpose of this study was to investigate the effect of FloTrac monitoring for target-guided fluid therapy on postoperative use of booster drugs and length of hospital stay in patients with pheochromocytoma surgery through a case cohort study, and to provide a theoretical basis for clinical application

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

纳入标准:①术后标本病理证实为良性。②美国麻醉医师学会(American Society of Anesthesiology,ASA)分级1-3级。③年龄在18-75岁之间

Inclusion criteria

Inclusion criteria: Postoperative specimen pathology confirmed benign American Society of Anesthesiology (ASA) grades 1-3 ages 18-75 years

排除标准:

排除标准:① 有嗜铬细胞瘤家族史;②腹腔镜手术术中转开腹;③行双侧肾上腺切除术患者;④ 异位嗜铬细胞瘤患者。

Exclusion criteria:

Exclusion criteria: family history of pheochromocytoma; Laparoscopy converted to laparotomy; Bilateral adrenal resection was performed. A patient with ectopic pheochromocytoma

研究实施时间:

Study execute time:

From 2020-12-07 00:00:00 To 2022-12-07 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-12-07 00:00:00 To 2022-12-07 00:00:00  

干预措施:

Interventions:

组别:

实验组

样本量:

30

Group:

experimental group

Sample size:

干预措施:

使用Flotrac

干预措施代码:

Intervention:

use Flotrac

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

辽宁省 

市(区县):

 

Country:

China 

Province:

Liaoning 

City:

 

单位(医院):

中国医科大学附属盛京医院 

单位级别:

三甲医院 

Institution
hospital:

Shengjing Hospital of China Medical University

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

术后升压药使用时间

指标类型:

主要指标

Outcome:

Use time of booster after operation

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后升压药使用剂量

指标类型:

主要指标

Outcome:

Postoperative dose of booster drug

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后住院天数

指标类型:

主要指标

Outcome:

Postoperative hospitalization days

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

no sample

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 75 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

实验组为Flotrac监测组由麻醉医生选取经我院伦理委员会审查同意后于我院行单侧腹腔镜或开腹嗜铬细胞瘤切除术患者30例;对照组麻醉医生回顾分析我院2015-2019年行单侧腹腔镜或开腹嗜铬细胞瘤切除术患者90例,术中采用IBP有创动脉压监测未使用Flotrac.

Randomization Procedure (please state who generates the random number sequence and by what method):

In the experimental group, 30 patients who underwent unilateral laparoscopic or open pheochromocytoma resection in our hospital after review and approval by our hospital ethics Committee were selected by anesthesiologists as Flotrac monitoring group. The anesthesiologists of the control group retrospectively analyzed 90 patien

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

实验完成后6个月内于本网站公开

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The experiment will be published on this website within 6 months after completion

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

case report form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2020-12-08 02:08:29